SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) shares saw strong trading volume on Wednesday . 498,347 shares changed hands during mid-day trading, an increase of 20% from the previous session’s volume of 416,329 shares.The stock last traded at $10.33 and had previously closed at $10.57.

The stock has a 50 day moving average price of $11.45 and a 200 day moving average price of $11.54. The company has a market capitalization of $499.39 million and a price-to-earnings ratio of 13.50.

SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter. The company had revenue of $39 million for the quarter, compared to analyst estimates of $37.90 million. On average, analysts anticipate that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.

In related news, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $10.62, for a total value of $82,857.24. Following the transaction, the chief financial officer now owns 25,000 shares in the company, valued at approximately $265,500. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Friedhelm Blobel sold 501,875 shares of the stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $10.00, for a total transaction of $5,018,750.00. Following the completion of the transaction, the chief executive officer now owns 588,255 shares in the company, valued at approximately $5,882,550. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in SciClone Pharmaceuticals stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 12.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,900 shares of the specialty pharmaceutical company’s stock after buying an additional 25,225 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.47% of SciClone Pharmaceuticals worth $2,143,000 as of its most recent filing with the SEC.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.